GlassScriptPhysician profile
Atish Patel
NPI 1265967103
$17,588.84
in general payments reported to CMS, 2019-2025
25 companies · $2,798 in 2025
The $2,798 reported for 2025 was more than what 88% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,001 · 2022: $627 · 2023: $4,189 · 2024: $8,974 · 2025: $2,798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,256 · Consulting Fee: $4,750 · Travel and Lodging: $2,955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,256.13 |
| Consulting Fee | $4,750.00 |
| Travel and Lodging | $2,955.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $10,161.61 | 2022-2025 | Evoke, Evoke Scs |
| Boston Scientific Corporation | $2,463.56 | 2021-2025 | Intracept, Wavewriter Alpha Prime 16, General - Pain Management |
| Medtronic, INC. | $1,666.34 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Abbott Laboratories | $1,100.14 | 2021-2025 | Eterna, Proclaim, Octrode |
| Nevro Corp. | $946.85 | 2021-2024 | Senza |
| Spinal Simplicity, LLC | $210.83 | 2024 | Ha Minuteman G3-R |
| Collegium Pharmaceutical, INC. | $191.85 | 2024-2025 | Xtampza, Belbuca |
| Vertos Medical, INC. | $175.64 | 2022-2024 | Mild Device Kit |
| Abbvie INC. | $137.69 | 2023-2025 | |
| Stimwave Technologies Incorporated | $86.56 | 2021-2022 | |
| Curonix LLC | $71.01 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Biotronik Nro, INC. | $69.48 | 2024 | Prospera |
| Vertex Pharmaceuticals Incorporated | $58.70 | 2025 | |
| Si-Bone, INC. | $31.44 | 2024 | |
| Merz Pharmaceuticals, LLC | $27.78 | 2023 | Xeomin |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $26.66 | 2024 | Zilretta, Iovera, Exparel |
| Relievant Medsystems, INC. | $24.36 | 2023 | Intracept |
| Foundation Fusion Solutions, LLC | $23.61 | 2024-2025 | |
| Globus Medical, INC. | $23.19 | 2025 | Senza |
| Impel Pharmaceuticals INC. | $22.23 | 2023 | Trudhesa |
| Fidia Pharma USA INC. | $17.34 | 2023 | Hymovis |
| Depuy Synthes Sales INC. | $14.70 | 2023 | Orthovisc |
| Kowa Pharmaceuticals America, INC. | $14.42 | 2023 | Seglentis |
| Grt US Holding, INC. | $12.32 | 2022 | |
| Spr Therapeutics, INC | $10.53 | 2023 | Sprint Pns System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atish Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.